A2002 |
Nivolumab (anti-PD-1)
|
Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. |
-
Cancer Cell, 2024, S1535-6108(24)00080-1
-
Cell Rep Med, 2024, S2666-3791(24)00241-6
-
Cell Rep Med, 2024, 5(2):101416
|
|
A2004 |
Atezolizumab (anti-PD-L1)
|
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. |
-
J Immunother Cancer, 2024, 12(5)e008669
-
Cell Death Dis, 2024, 15(2):175
-
Int Immunopharmacol, 2024,
|
|
A2005 |
Pembrolizumab (anti-PD-1)
|
Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. |
-
Nat Med, 2024, 10.1038/s41591-024-02824-y
-
Cell Mol Immunol, 2024, 21(1):60-79
-
Cell Rep Med, 2024, S2666-3791(24)00196-4
|
|
S7912 |
BMS202
|
BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
|
-
Phytomedicine, 2024, 125:155370
-
J Med Chem, 2024, 67(5):4036-4062
-
Comput Struct Biotechnol J, 2023, 21:3355-3368
|
|
A2013 |
Durvalumab (anti-PD-L1)
|
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. |
-
J Biol Chem, 2024, S0021-9258(24)01826-X
-
Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
-
Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
|
|
S7911 |
BMS-1
|
BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM. |
-
J Med Chem, 2024, 67(5):4036-4062
-
Int. J. Mol. Sci, 2023, 24(4)
-
Int J Mol Sci, 2023, 24(4)3971
|
|
S8158 |
PD-1/PD-L1 Inhibitor 3
|
PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM |
-
ACS Appl Mater Interfaces, 2024, 16(18):22839-49
-
J Med Chem, 2024, 67(5):4036-4062
-
Pharmaceuticals (Basel), 2023, 16(7)1051
|
|
S8275 |
Tomivosertib (eFT-508)
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
-
PLoS Biol, 2023, 21(8):e3002227
-
Hum Exp Toxicol, 2023, 42:9603271231158047
-
JCI Insight, 2022, 7(22e158060)
|
|
S8859 |
BMS-1166
|
BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM. |
-
Life Sci Alliance, 2024, 10.26508/lsa.202302461
-
Int J Biol Sci, 2023, 19(14):4627-4643
-
Int J Biol Sci, 2023, 19(14):4627-4643
|
|
S8549 |
AUNP-12
|
AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. |
-
Acta Pharm Sin B, 2024, 14(1):350-364
-
Carcinogenesis, 2022, bgac043
-
Molecules, 2019, 24(15)
|
|
S0094 |
SR 0987
|
SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer. |
-
Evid Based Complement Alternat Med, 2022, 2022:8315503
|
|
A2017 |
Spartalizumab (anti-PD-1)
|
Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD. |
-
Elife, 2020, 9
|
|
E1322New |
GS-4224
|
GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions. |
|
|
S8473New |
CA-170 (AUPM-170)
|
CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy. |
|
|
A2122 |
Anti-mouse PD-1 (CD279)-InVivo
|
Anti-mouse PD-1 (CD279)-InVivo(Clone:RMP1-14) reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. |
-
Cancer Lett, 2024, 588:216814
|
|
S9610 |
BMS-1001
|
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. |
|
|
E3151 |
Sanguisorbae Radix Extract
|
Sanguisorbae Radix Extract is extracted from Sanguisorbae Radix, which has anticancer effects by inhibiting PD-1/PD-L1 and also enhances immuno-oncologic effects. |
|
|
A2035 |
Sintilimab (anti-PD-1)
|
Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. |
|
|
S9863 |
INCB086550
|
INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization. |
|
|
A2775New |
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274)
|
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD. |
|
|
A2016 |
Camrelizumab (anti-PD-1)
|
Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD. |
-
Life Sci Alliance, 2024, 7(3)e202302368
|
|
A2122 |
Anti-mouse PD-1 (CD279)-InVivo
|
Anti-mouse PD-1 (CD279)-InVivo(Clone:RMP1-14) reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. |
- Cancer Lett, 2024, 588:216814
|
|
A2035 |
Sintilimab (anti-PD-1)
|
Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. |
|
|
A2775New |
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274)
|
Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD. |
|
|
S7912 |
BMS202
|
BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
|
- Phytomedicine, 2024, 125:155370
- J Med Chem, 2024, 67(5):4036-4062
- Comput Struct Biotechnol J, 2023, 21:3355-3368
|
|
S7911 |
BMS-1
|
BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM. |
- J Med Chem, 2024, 67(5):4036-4062
- Int. J. Mol. Sci, 2023, 24(4)
- Int J Mol Sci, 2023, 24(4)3971
|
|
S8158 |
PD-1/PD-L1 Inhibitor 3
|
PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM |
- ACS Appl Mater Interfaces, 2024, 16(18):22839-49
- J Med Chem, 2024, 67(5):4036-4062
- Pharmaceuticals (Basel), 2023, 16(7)1051
|
|
S8275 |
Tomivosertib (eFT-508)
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
- PLoS Biol, 2023, 21(8):e3002227
- Hum Exp Toxicol, 2023, 42:9603271231158047
- JCI Insight, 2022, 7(22e158060)
|
|
S8859 |
BMS-1166
|
BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM. |
- Life Sci Alliance, 2024, 10.26508/lsa.202302461
- Int J Biol Sci, 2023, 19(14):4627-4643
- Int J Biol Sci, 2023, 19(14):4627-4643
|
|
S8549 |
AUNP-12
|
AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. |
- Acta Pharm Sin B, 2024, 14(1):350-364
- Carcinogenesis, 2022, bgac043
- Molecules, 2019, 24(15)
|
|
S0094 |
SR 0987
|
SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer. |
- Evid Based Complement Alternat Med, 2022, 2022:8315503
|
|
E1322New |
GS-4224
|
GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions. |
|
|
S8473New |
CA-170 (AUPM-170)
|
CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy. |
|
|
S9610 |
BMS-1001
|
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. |
|
|
E3151 |
Sanguisorbae Radix Extract
|
Sanguisorbae Radix Extract is extracted from Sanguisorbae Radix, which has anticancer effects by inhibiting PD-1/PD-L1 and also enhances immuno-oncologic effects. |
|
|
S9863 |
INCB086550
|
INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization. |
|
|
A2002 |
Nivolumab (anti-PD-1)
|
Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. |
- Cancer Cell, 2024, S1535-6108(24)00080-1
- Cell Rep Med, 2024, S2666-3791(24)00241-6
- Cell Rep Med, 2024, 5(2):101416
|
|
A2004 |
Atezolizumab (anti-PD-L1)
|
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. |
- J Immunother Cancer, 2024, 12(5)e008669
- Cell Death Dis, 2024, 15(2):175
- Int Immunopharmacol, 2024,
|
|
A2005 |
Pembrolizumab (anti-PD-1)
|
Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. |
- Nat Med, 2024, 10.1038/s41591-024-02824-y
- Cell Mol Immunol, 2024, 21(1):60-79
- Cell Rep Med, 2024, S2666-3791(24)00196-4
|
|
A2013 |
Durvalumab (anti-PD-L1)
|
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. |
- J Biol Chem, 2024, S0021-9258(24)01826-X
- Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
- Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
|
|
A2017 |
Spartalizumab (anti-PD-1)
|
Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD. |
- Elife, 2020, 9
|
|
A2016 |
Camrelizumab (anti-PD-1)
|
Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD. |
- Life Sci Alliance, 2024, 7(3)e202302368
|
|